{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04952597",
      "orgStudyIdInfo": {
        "id": "AdvanTIG-204"
      },
      "secondaryIdInfos": [
        {
          "id": "CTR20211531",
          "type": "OTHER",
          "domain": "ChinaDrugTrials"
        },
        {
          "id": "BGB-A317-A1217-204",
          "type": "OTHER",
          "domain": "BeiGene ID"
        }
      ],
      "organization": {
        "fullName": "BeiGene",
        "class": "INDUSTRY"
      },
      "briefTitle": "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer",
      "officialTitle": "A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-10",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-07-15",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-07-26",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-07-26",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-06-28",
      "studyFirstSubmitQcDate": "2021-06-28",
      "studyFirstPostDateStruct": {
        "date": "2021-07-07",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2024-07-16",
      "resultsFirstSubmitQcDate": "2024-08-16",
      "resultsFirstPostDateStruct": {
        "date": "2024-09-19",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-10-23",
      "lastUpdatePostDateStruct": {
        "date": "2024-10-26",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "BeiGene",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants ."
    },
    "conditionsModule": {
      "conditions": [
        "Limited Stage Small Cell Lung Cancer"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 126,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Arm A: Ociperlimab + Tislelizumab",
          "type": "EXPERIMENTAL",
          "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab",
          "interventionNames": [
            "Drug: Ociperlimab",
            "Drug: Tislelizumab",
            "Drug: Concurrent Chemoradiotherapy"
          ]
        },
        {
          "label": "Arm B: Tislelizumab",
          "type": "EXPERIMENTAL",
          "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone",
          "interventionNames": [
            "Drug: Tislelizumab",
            "Drug: Concurrent Chemoradiotherapy"
          ]
        },
        {
          "label": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
          "type": "EXPERIMENTAL",
          "description": "cCRT only for 4 cycles at the investigator's discretion",
          "interventionNames": [
            "Drug: Concurrent Chemoradiotherapy"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Ociperlimab",
          "description": "Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle",
          "armGroupLabels": [
            "Arm A: Ociperlimab + Tislelizumab"
          ],
          "otherNames": [
            "BGB-A1217"
          ]
        },
        {
          "type": "DRUG",
          "name": "Tislelizumab",
          "description": "Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle",
          "armGroupLabels": [
            "Arm A: Ociperlimab + Tislelizumab",
            "Arm B: Tislelizumab"
          ],
          "otherNames": [
            "BGB-A317"
          ]
        },
        {
          "type": "DRUG",
          "name": "Concurrent Chemoradiotherapy",
          "description": "Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)",
          "armGroupLabels": [
            "Arm A: Ociperlimab + Tislelizumab",
            "Arm B: Tislelizumab",
            "Arm C: Concurrent Chemoradiotherapy (cCRT)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Progression Free Survival (PFS)",
          "description": "Defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)",
          "timeFrame": "Up to approximately 2 years"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Complete Response Rate (CR)",
          "description": "defined as the percentage of participants who had CR as assessed by the investigator per RECIST v1.1",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Overall Response Rate (ORR)",
          "description": "defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Overall Response Rate (ORR) in the Programmed Death-Ligand 1 (PD-L1) Analysis Set",
          "description": "defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Overall Response Rate (ORR) in the T Cell Immunoreceptor With Immunoglobulin and ITIM Domain (TIGIT) Analysis Set",
          "description": "defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Duration of Response (DOR)",
          "description": "defined as the time from the date of the first occurrence of a documented objective response to the date of documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Overall Survival (OS) in the ITT Analysis Set",
          "description": "Defined as the time from the date of randomization to the date of death due to any cause",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Overall Survival (OS) in the PD-L1 Analysis Set",
          "description": "defined as the time from the date of randomization to the date of death due to any cause",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Overall Survival (OS) in the TIGIT Analysis Set",
          "description": "defined as the time from the date of randomization to the date of death due to any cause",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Distant Metastasis-free Survival (DMFS)",
          "description": "defined as the time from the date of randomization to the date of the first documented distant metastasis as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "PFS in the PD-L1 Analysis Set",
          "description": "defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "PFS in the TIGIT Analysis Set",
          "description": "defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),",
          "timeFrame": "Up to approximately 2 years"
        },
        {
          "measure": "Number of Participants Experiencing Adverse Events (AEs)",
          "description": "Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.03",
          "timeFrame": "From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Participant has pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer\n* Has limited-stage disease (stage Tx, T1-T4, N0-3, M0; AJCC staging, 8th edition), and can be safely treated with definitive radiation doses.\n* Participant has not received any prior treatment for LS-SCLC.\n* Participant has measurable disease as assessed according to RECIST v1.1 that is appropriate for selection as a target lesion for repeat measurement, as determined by local site investigator/radiology review\n* ECOG Performance Status ≤ 2 assessed within 7 days before the first administration of study intervention, and must have a life expectancy of ≥ 12 weeks.\n\nKey Exclusion Criteria:\n\n* Mixed small cell lung cancer histology. Note: mixed SCLC with the component of neuroendocrine carcinoma origin is considered eligible\n* Have received surgical resection for LS-SCLC\n* Any participant for whom the tumor is considered resectable by surgery or stereotactic body radiation therapy/stereotactic ablative radiotherapy should be considered ineligible\n* Is expected to require any other form of antineoplastic therapy while on study.\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways\n\nNote: Other protocol-defined Inclusion/Exclusion criteria may apply",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "BeiGene",
          "affiliation": "Study Director",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Tennessee Cancer Specialist",
          "city": "Knoxville",
          "state": "Tennessee",
          "zip": "37909",
          "country": "United States",
          "geoPoint": {
            "lat": 35.96064,
            "lon": -83.92074
          }
        },
        {
          "facility": "Peking University First Hospital",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100034",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Beijing Cancer Hospital",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100142",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Gansu Provincial Cancer Hospital",
          "city": "Lanzhou",
          "state": "Gansu",
          "zip": "730050",
          "country": "China",
          "geoPoint": {
            "lat": 36.05701,
            "lon": 103.83987
          }
        },
        {
          "facility": "The First Affiliated Hospital, Sun Yat Sen University",
          "city": "Guangzhou",
          "state": "Guangdong",
          "zip": "510080",
          "country": "China",
          "geoPoint": {
            "lat": 23.11667,
            "lon": 113.25
          }
        },
        {
          "facility": "The Tumor Hospital Affiliated to Guangxi Medical University",
          "city": "Nanning",
          "state": "Guangxi",
          "zip": "530021",
          "country": "China",
          "geoPoint": {
            "lat": 22.81667,
            "lon": 108.31667
          }
        },
        {
          "facility": "Henan Cancer Hospital",
          "city": "Zhengzhou",
          "state": "Henan",
          "zip": "450000",
          "country": "China",
          "geoPoint": {
            "lat": 34.75778,
            "lon": 113.64861
          }
        },
        {
          "facility": "The First Affiliated Hospital of Zhengzhou University",
          "city": "Zhengzhou",
          "state": "Henan",
          "zip": "450052",
          "country": "China",
          "geoPoint": {
            "lat": 34.75778,
            "lon": 113.64861
          }
        },
        {
          "facility": "Union Hospital of Tongji Medical College, Huazhong University of Science and Technology",
          "city": "Wuhan",
          "state": "Hubei",
          "zip": "430022",
          "country": "China",
          "geoPoint": {
            "lat": 30.58333,
            "lon": 114.26667
          }
        },
        {
          "facility": "The Second Xiangya Hospital of Central South University",
          "city": "Changsha",
          "state": "Hunan",
          "zip": "410011",
          "country": "China",
          "geoPoint": {
            "lat": 28.19874,
            "lon": 112.97087
          }
        },
        {
          "facility": "Hunan Cancer Hospital",
          "city": "Changsha",
          "state": "Hunan",
          "zip": "410013",
          "country": "China",
          "geoPoint": {
            "lat": 28.19874,
            "lon": 112.97087
          }
        },
        {
          "facility": "Huai An First Peoples Hospital",
          "city": "Huaian",
          "state": "Jiangsu",
          "zip": "223300",
          "country": "China"
        },
        {
          "facility": "Nanjing Chest Hospital",
          "city": "Nanjing",
          "state": "Jiangsu",
          "zip": "210029",
          "country": "China",
          "geoPoint": {
            "lat": 32.06167,
            "lon": 118.77778
          }
        },
        {
          "facility": "The Affiliated Hospital of Xuzhou Medical University",
          "city": "Xuzhou",
          "state": "Jiangsu",
          "zip": "221000",
          "country": "China",
          "geoPoint": {
            "lat": 34.20442,
            "lon": 117.28386
          }
        },
        {
          "facility": "Hanzhong Central Hospital",
          "city": "Hanzhong",
          "state": "Shaanxi",
          "zip": "72300",
          "country": "China",
          "geoPoint": {
            "lat": 33.07507,
            "lon": 107.02214
          }
        },
        {
          "facility": "Qilu Hospital of Shandong University",
          "city": "Jinan",
          "state": "Shandong",
          "zip": "250000",
          "country": "China",
          "geoPoint": {
            "lat": 36.66833,
            "lon": 116.99722
          }
        },
        {
          "facility": "Linyi Cancer Hospital",
          "city": "Linyi",
          "state": "Shandong",
          "zip": "276001",
          "country": "China",
          "geoPoint": {
            "lat": 35.06306,
            "lon": 118.34278
          }
        },
        {
          "facility": "Qingdao Central Hospital",
          "city": "Qingdao",
          "state": "Shandong",
          "zip": "266031",
          "country": "China",
          "geoPoint": {
            "lat": 36.06488,
            "lon": 120.38042
          }
        },
        {
          "facility": "Yantai Yuhuangding Hospital",
          "city": "Yantai",
          "state": "Shandong",
          "zip": "264000",
          "country": "China",
          "geoPoint": {
            "lat": 37.47649,
            "lon": 121.44081
          }
        },
        {
          "facility": "Fudan University Shanghai Cancer Center",
          "city": "Shanghai",
          "state": "Shanghai Municipality",
          "zip": "200000",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        },
        {
          "facility": "Affiliated Zhongshan Hospital of Fudan University",
          "city": "Shanghai",
          "state": "Shanghai Municipality",
          "zip": "200032",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        },
        {
          "facility": "West China Hospital, Sichuan University",
          "city": "Chengdu",
          "state": "Sichuan",
          "zip": "610041",
          "country": "China",
          "geoPoint": {
            "lat": 30.66667,
            "lon": 104.06667
          }
        },
        {
          "facility": "Affiliated Hospital of North Sichuan Medical College",
          "city": "Nanchong",
          "state": "Sichuan",
          "zip": "637000",
          "country": "China",
          "geoPoint": {
            "lat": 30.79508,
            "lon": 106.08473
          }
        },
        {
          "facility": "Tianjin Medical University General Hospital",
          "city": "Tianjin",
          "state": "Tianjin Municipality",
          "zip": "300052",
          "country": "China",
          "geoPoint": {
            "lat": 39.14222,
            "lon": 117.17667
          }
        },
        {
          "facility": "Tianjin Medical University Cancer Institute and Hospital",
          "city": "Tianjin",
          "state": "Tianjin Municipality",
          "zip": "300060",
          "country": "China",
          "geoPoint": {
            "lat": 39.14222,
            "lon": 117.17667
          }
        },
        {
          "facility": "The Second Affiliated Hospital of Kunming Medical University",
          "city": "Kunming",
          "state": "Yunnan",
          "zip": "650000",
          "country": "China",
          "geoPoint": {
            "lat": 25.03889,
            "lon": 102.71833
          }
        },
        {
          "facility": "Zhejiang Cancer Hospital",
          "city": "Hangzhou",
          "state": "Zhejiang",
          "zip": "310022",
          "country": "China",
          "geoPoint": {
            "lat": 30.29365,
            "lon": 120.16142
          }
        },
        {
          "facility": "Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)",
          "city": "Ningbo",
          "state": "Zhejiang",
          "zip": "315000",
          "country": "China",
          "geoPoint": {
            "lat": 29.87819,
            "lon": 121.54945
          }
        },
        {
          "facility": "Chungbuk National University Hospital",
          "city": "Cheongju-si",
          "state": "Chungcheongbukdo",
          "zip": "28644",
          "country": "South Korea",
          "geoPoint": {
            "lat": 36.63722,
            "lon": 127.48972
          }
        },
        {
          "facility": "Cha Bundang Medical Center, Cha University",
          "city": "Gyeonggido",
          "state": "Gyeonggi-do",
          "zip": "13496",
          "country": "South Korea"
        },
        {
          "facility": "The Catholic University of Korea, St Vincents Hospital",
          "city": "Suwon",
          "state": "Gyeonggi-do",
          "zip": "16247",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.29111,
            "lon": 127.00889
          }
        },
        {
          "facility": "Ajou University Hospital",
          "city": "Suwon",
          "state": "Gyeonggi-do",
          "zip": "16499",
          "country": "South Korea",
          "geoPoint": {
            "lat": 37.29111,
            "lon": 127.00889
          }
        },
        {
          "facility": "Kyungpook National University Chilgok Hospital",
          "city": "Daegu",
          "state": "Gyeongsangbukdo",
          "zip": "41404",
          "country": "South Korea",
          "geoPoint": {
            "lat": 35.87028,
            "lon": 128.59111
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "type": "BACKGROUND",
          "citation": "Youling Gong, Qingsong Pang, Rong Yu, Zhengfei Zhu, Jiangqiong Huang, Yufeng Cheng, Diansheng Zhong, Hongbo Wu, Seung Soo Yoo, Tracy Dobbs, Zinan Bao, Yunxia Zuo, Boxian Wei, Pu Sun, You Lu; Abstract CT255: AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC). Cancer Res 1 April 2024; 84 (7_Supplement): CT255. https://doi.org/10.1158/1538-7445.AM2024-CT255"
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "recruitmentDetails": "Participants were enrolled in multiple study centers in China, South Korea, and the United States.",
      "groups": [
        {
          "id": "FG000",
          "title": "Arm A: Ociperlimab + Tislelizumab",
          "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
        },
        {
          "id": "FG001",
          "title": "Arm B: Tislelizumab",
          "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
        },
        {
          "id": "FG002",
          "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
          "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "41"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "42"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "43"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "28"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "28"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "25"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "13"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "14"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "18"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Death",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "12"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "13"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "14"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "3"
                }
              ]
            },
            {
              "type": "Lost to Follow-up",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "populationDescription": "The Intent-To-Treat (ITT) Analysis Set includes all randomized patients.",
      "groups": [
        {
          "id": "BG000",
          "title": "Arm A: Ociperlimab + Tislelizumab",
          "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
        },
        {
          "id": "BG001",
          "title": "Arm B: Tislelizumab",
          "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
        },
        {
          "id": "BG002",
          "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
          "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
        },
        {
          "id": "BG003",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "41"
            },
            {
              "groupId": "BG001",
              "value": "42"
            },
            {
              "groupId": "BG002",
              "value": "43"
            },
            {
              "groupId": "BG003",
              "value": "126"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "60.5",
                      "spread": "9.50"
                    },
                    {
                      "groupId": "BG001",
                      "value": "59.9",
                      "spread": "7.11"
                    },
                    {
                      "groupId": "BG002",
                      "value": "61.0",
                      "spread": "9.54"
                    },
                    {
                      "groupId": "BG003",
                      "value": "60.5",
                      "spread": "8.73"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "9"
                    },
                    {
                      "groupId": "BG002",
                      "value": "8"
                    },
                    {
                      "groupId": "BG003",
                      "value": "27"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "31"
                    },
                    {
                      "groupId": "BG001",
                      "value": "33"
                    },
                    {
                      "groupId": "BG002",
                      "value": "35"
                    },
                    {
                      "groupId": "BG003",
                      "value": "99"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race/Ethnicity, Customized",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "title": "Asian",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "41"
                    },
                    {
                      "groupId": "BG001",
                      "value": "42"
                    },
                    {
                      "groupId": "BG002",
                      "value": "42"
                    },
                    {
                      "groupId": "BG003",
                      "value": "125"
                    }
                  ]
                }
              ]
            },
            {
              "title": "White",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Progression Free Survival (PFS)",
          "description": "Defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)",
          "populationDescription": "The ITT analysis set includes all randomized participants",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "41"
                },
                {
                  "groupId": "OG001",
                  "value": "42"
                },
                {
                  "groupId": "OG002",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "12.6",
                      "lowerLimit": "8.7",
                      "upperLimit": "NA",
                      "comment": "NA: Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "13.2",
                      "lowerLimit": "8.5",
                      "upperLimit": "NA",
                      "comment": "NA: Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "9.5",
                      "lowerLimit": "8.3",
                      "upperLimit": "14.4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Complete Response Rate (CR)",
          "description": "defined as the percentage of participants who had CR as assessed by the investigator per RECIST v1.1",
          "populationDescription": "The Intent-To-Treat (ITT) analysis set includes all randomized participants",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "41"
                },
                {
                  "groupId": "OG001",
                  "value": "42"
                },
                {
                  "groupId": "OG002",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "7.3",
                      "lowerLimit": "1.5",
                      "upperLimit": "19.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "9.5",
                      "lowerLimit": "2.7",
                      "upperLimit": "22.6"
                    },
                    {
                      "groupId": "OG002",
                      "value": "2.3",
                      "lowerLimit": "0.1",
                      "upperLimit": "12.3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Response Rate (ORR)",
          "description": "defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1",
          "populationDescription": "The Intent-To-Treat (ITT) analysis set includes all randomized participants",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "41"
                },
                {
                  "groupId": "OG001",
                  "value": "42"
                },
                {
                  "groupId": "OG002",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "85.4",
                      "lowerLimit": "70.8",
                      "upperLimit": "94.4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "88.1",
                      "lowerLimit": "74.4",
                      "upperLimit": "96.0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "76.7",
                      "lowerLimit": "61.4",
                      "upperLimit": "88.2"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Response Rate (ORR) in the Programmed Death-Ligand 1 (PD-L1) Analysis Set",
          "description": "defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1",
          "populationDescription": "The PD-L1 Analysis Set includes all patients who have at least 1 evaluable PD-L1 measurement expressed by Tumor Area Percentage (TAP).",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "30"
                },
                {
                  "groupId": "OG001",
                  "value": "28"
                },
                {
                  "groupId": "OG002",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "PD-L1 Expression in TAP ( >=1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    },
                    {
                      "groupId": "OG001",
                      "value": "17"
                    },
                    {
                      "groupId": "OG002",
                      "value": "17"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "85.7",
                      "lowerLimit": "57.2",
                      "upperLimit": "98.2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "94.1",
                      "lowerLimit": "71.3",
                      "upperLimit": "99.9"
                    },
                    {
                      "groupId": "OG002",
                      "value": "76.5",
                      "lowerLimit": "50.1",
                      "upperLimit": "93.2"
                    }
                  ]
                }
              ]
            },
            {
              "title": "PD-L1 Expression in TAP (<1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "16"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    },
                    {
                      "groupId": "OG002",
                      "value": "15"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "93.8",
                      "lowerLimit": "69.8",
                      "upperLimit": "99.8"
                    },
                    {
                      "groupId": "OG001",
                      "value": "81.8",
                      "lowerLimit": "48.2",
                      "upperLimit": "97.7"
                    },
                    {
                      "groupId": "OG002",
                      "value": "86.7",
                      "lowerLimit": "59.5",
                      "upperLimit": "98.3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Response Rate (ORR) in the T Cell Immunoreceptor With Immunoglobulin and ITIM Domain (TIGIT) Analysis Set",
          "description": "defined as the percentage of participants who had CR or partial response (PR) as assessed by the investigator per RECIST v1.1",
          "populationDescription": "The TIGIT Analysis Set includes all patients who have at least 1 evaluable TIGIT measurement expressed by Immune Cells (IC) percentage.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "33"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                },
                {
                  "groupId": "OG002",
                  "value": "35"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "TIGIT Expression Level in IC (>=1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "18"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    },
                    {
                      "groupId": "OG002",
                      "value": "16"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "88.9",
                      "lowerLimit": "65.3",
                      "upperLimit": "98.6"
                    },
                    {
                      "groupId": "OG001",
                      "value": "88.0",
                      "lowerLimit": "68.8",
                      "upperLimit": "97.5"
                    },
                    {
                      "groupId": "OG002",
                      "value": "93.8",
                      "lowerLimit": "69.8",
                      "upperLimit": "99.8"
                    }
                  ]
                }
              ]
            },
            {
              "title": "TIGIT Expression Level in IC (<1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    },
                    {
                      "groupId": "OG001",
                      "value": "7"
                    },
                    {
                      "groupId": "OG002",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "86.7",
                      "lowerLimit": "59.5",
                      "upperLimit": "98.3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "100.0",
                      "lowerLimit": "59.0",
                      "upperLimit": "100.0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "68.4",
                      "lowerLimit": "43.4",
                      "upperLimit": "84.4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Duration of Response (DOR)",
          "description": "defined as the time from the date of the first occurrence of a documented objective response to the date of documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)",
          "populationDescription": "The ITT analysis set included all randomized participants; only participants with an objective response (CR or PR) were included in this analysis",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "35"
                },
                {
                  "groupId": "OG001",
                  "value": "37"
                },
                {
                  "groupId": "OG002",
                  "value": "33"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "10.1",
                      "lowerLimit": "6.0",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11.5",
                      "lowerLimit": "6.9",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "8.2",
                      "lowerLimit": "5.6",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Survival (OS) in the ITT Analysis Set",
          "description": "Defined as the time from the date of randomization to the date of death due to any cause",
          "populationDescription": "The Intent-To-Treat (ITT) analysis set includes all randomized participants",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "41"
                },
                {
                  "groupId": "OG001",
                  "value": "42"
                },
                {
                  "groupId": "OG002",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "19.8",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "lowerLimit": "20.0",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Survival (OS) in the PD-L1 Analysis Set",
          "description": "defined as the time from the date of randomization to the date of death due to any cause",
          "populationDescription": "The PD-L1 Analysis Set includes all patients who have at least 1 evaluable PD-L1 measurement expressed by Tumor Area Percentage (TAP).",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "30"
                },
                {
                  "groupId": "OG001",
                  "value": "28"
                },
                {
                  "groupId": "OG002",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "PD-L1 Expression in TAP (>=1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    },
                    {
                      "groupId": "OG001",
                      "value": "17"
                    },
                    {
                      "groupId": "OG002",
                      "value": "17"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "12.2",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the PD-L1 expression subgroups due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "17.6",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the PD-L1 expression subgroups due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "lowerLimit": "16.5",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the PD-L1 expression subgroups due to too few events to draw any meaningful conclusions"
                    }
                  ]
                }
              ]
            },
            {
              "title": "PD-L1 Expression in TAP (<1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "16"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    },
                    {
                      "groupId": "OG002",
                      "value": "15"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "13.1",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the PD-L1 expression subgroups due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "7.3",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the PD-L1 expression subgroups due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "lowerLimit": "13.3",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the PD-L1 expression subgroups due to too few events to draw any meaningful conclusions"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Survival (OS) in the TIGIT Analysis Set",
          "description": "defined as the time from the date of randomization to the date of death due to any cause",
          "populationDescription": "The TIGIT Analysis Set includes all patients who have at least 1 evaluable TIGIT measurement expressed by immune cells percentage.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "33"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                },
                {
                  "groupId": "OG002",
                  "value": "35"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "TIGIT Expression Level in IC (>=1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "18"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    },
                    {
                      "groupId": "OG002",
                      "value": "16"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the TIGIT expression subgroups, due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the TIGIT expression subgroups, due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "lowerLimit": "20.0",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the TIGIT expression subgroups, due to too few events to draw any meaningful conclusions"
                    }
                  ]
                }
              ]
            },
            {
              "title": "TIGIT Expression Level in IC (<1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    },
                    {
                      "groupId": "OG001",
                      "value": "7"
                    },
                    {
                      "groupId": "OG002",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "12.0",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the TIGIT expression subgroups, due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "17.6",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the TIGIT expression subgroups, due to too few events to draw any meaningful conclusions"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "lowerLimit": "13.3",
                      "upperLimit": "NA",
                      "comment": "the median OS was not reached in the TIGIT expression subgroups, due to too few events to draw any meaningful conclusions"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Distant Metastasis-free Survival (DMFS)",
          "description": "defined as the time from the date of randomization to the date of the first documented distant metastasis as assessed by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)",
          "populationDescription": "The Intent-To-Treat (ITT) analysis set includes all randomized participants",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "41"
                },
                {
                  "groupId": "OG001",
                  "value": "42"
                },
                {
                  "groupId": "OG002",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "17.9",
                      "lowerLimit": "9.7",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15.3",
                      "lowerLimit": "9.8",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "20.0",
                      "lowerLimit": "8.6",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "PFS in the PD-L1 Analysis Set",
          "description": "defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),",
          "populationDescription": "The PD-L1 Analysis Set includes all patients who have at least 1 evaluable PD-L1 measurement expressed by Tumor Area Percentage (TAP).",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "30"
                },
                {
                  "groupId": "OG001",
                  "value": "28"
                },
                {
                  "groupId": "OG002",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "PD-L1 Expression in TAP ( >=1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    },
                    {
                      "groupId": "OG001",
                      "value": "17"
                    },
                    {
                      "groupId": "OG002",
                      "value": "17"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "12.6",
                      "lowerLimit": "7.8",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15.0",
                      "lowerLimit": "8.5",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "11.1",
                      "lowerLimit": "8.1",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            },
            {
              "title": "PD-L1 Expression in TAP (<1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "16"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    },
                    {
                      "groupId": "OG002",
                      "value": "15"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "10.3",
                      "lowerLimit": "5.7",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "14.8",
                      "lowerLimit": "4.0",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "14.4",
                      "lowerLimit": "7.9",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "PFS in the TIGIT Analysis Set",
          "description": "defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first),",
          "populationDescription": "The TIGIT Analysis Set includes all patients who have at least 1 evaluable TIGIT measurement expressed by immune cells percentage.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "33"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                },
                {
                  "groupId": "OG002",
                  "value": "35"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "TIGIT Expression Level in IC (>=1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "18"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    },
                    {
                      "groupId": "OG002",
                      "value": "16"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "17.9",
                      "lowerLimit": "9.5",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG001",
                      "value": "14.3",
                      "lowerLimit": "7.1",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "11.2",
                      "lowerLimit": "8.3",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            },
            {
              "title": "TIGIT Expression Level in IC (<1%)",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    },
                    {
                      "groupId": "OG001",
                      "value": "7"
                    },
                    {
                      "groupId": "OG002",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "8.7",
                      "lowerLimit": "5.5",
                      "upperLimit": "12.6"
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "8.3",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    },
                    {
                      "groupId": "OG002",
                      "value": "14.4",
                      "lowerLimit": "7.2",
                      "upperLimit": "NA",
                      "comment": "Not estimable due to insufficient number of participants with events"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants Experiencing Adverse Events (AEs)",
          "description": "Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.03",
          "populationDescription": "The Safety Analysis Set includes all patients who have received \\>= 1 dose of any component of study drug.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years",
          "groups": [
            {
              "id": "OG000",
              "title": "Arm A: Ociperlimab + Tislelizumab",
              "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab\n\nOciperlimab: Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG001",
              "title": "Arm B: Tislelizumab",
              "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone\n\nTislelizumab: Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            },
            {
              "id": "OG002",
              "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
              "description": "cCRT only for 4 cycles at the investigator's discretion\n\nConcurrent Chemoradiotherapy: Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.\n\nEtoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles\n\nThoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "41"
                },
                {
                  "groupId": "OG001",
                  "value": "42"
                },
                {
                  "groupId": "OG002",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Number of Participants with at least one TEAE",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "41"
                    },
                    {
                      "groupId": "OG001",
                      "value": "42"
                    },
                    {
                      "groupId": "OG002",
                      "value": "43"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Number of participants with at least one SAE",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "25"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    },
                    {
                      "groupId": "OG002",
                      "value": "12"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "3",
      "timeFrame": "All-cause mortality and adverse events (AEs): From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years",
      "description": "All-cause mortality is reported for all randomized participants. Serious and other adverse events include all randomized participants who received ≥ 1 dose of any study treatment AEs are defined as events that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study treatment up to 30 days following study treatment discontinuation or initiation of a new anticancer therapy, whichever occurred first.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Arm A: Ociperlimab + Tislelizumab",
          "description": "Ociperlimab plus tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles (each cycle is 28 days), followed by ociperlimab plus tislelizumab",
          "deathsNumAffected": 12,
          "deathsNumAtRisk": 41,
          "seriousNumAffected": 25,
          "seriousNumAtRisk": 41,
          "otherNumAffected": 41,
          "otherNumAtRisk": 41
        },
        {
          "id": "EG001",
          "title": "Arm B: Tislelizumab",
          "description": "Tislelizumab combined with cCRT (at the investigator's discretion) for 4 cycles, followed by tislelizumab alone",
          "deathsNumAffected": 13,
          "deathsNumAtRisk": 42,
          "seriousNumAffected": 20,
          "seriousNumAtRisk": 42,
          "otherNumAffected": 42,
          "otherNumAtRisk": 42
        },
        {
          "id": "EG002",
          "title": "Arm C: Concurrent Chemoradiotherapy (cCRT)",
          "description": "cCRT only for 4 cycles at the investigator's discretion",
          "deathsNumAffected": 14,
          "deathsNumAtRisk": 43,
          "seriousNumAffected": 12,
          "seriousNumAtRisk": 43,
          "otherNumAffected": 43,
          "otherNumAtRisk": 43
        }
      ],
      "seriousEvents": [
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Febrile neutropenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Arteriosclerosis coronary artery",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Cardiac failure",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Immune-mediated enterocolitis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Oesophageal fistula",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Oesophageal perforation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pancreatitis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Upper gastrointestinal haemorrhage",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "COVID-19",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "COVID-19 pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pneumonia bacterial",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Sepsis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Septic shock",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Sinusitis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Foreign body in gastrointestinal tract",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Radiation oesophagitis",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Radiation pneumonitis",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Lymphocyte count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Myocardial necrosis marker increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Neutrophil count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Platelet count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "White blood cell count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypokalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hyponatraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Rotator cuff syndrome",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Ataxia",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Immune-mediated optic neuritis",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Immune-mediated lung disease",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Interstitial lung disease",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pneumonitis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pneumothorax",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Respiratory failure",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 72,
              "numAffected": 37,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 79,
              "numAffected": 38,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 48,
              "numAffected": 38,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Leukopenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 11,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 14,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Neutropenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 15,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Thrombocytopenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Sinus tachycardia",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Supraventricular tachycardia",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hyperthyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypothyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 11,
              "numAffected": 11,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Abdominal distension",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Abdominal pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Abdominal pain upper",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Constipation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 43,
              "numAffected": 24,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 35,
              "numAffected": 19,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 20,
              "numAffected": 13,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Dyspepsia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Dysphagia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 7,
              "numAffected": 7,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Eructation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Gastric dilatation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Gastritis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Gastrooesophageal reflux disease",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 73,
              "numAffected": 34,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 81,
              "numAffected": 32,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 57,
              "numAffected": 28,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Reflux gastritis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Toothache",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 40,
              "numAffected": 22,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 67,
              "numAffected": 29,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 33,
              "numAffected": 15,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Asthenia",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 14,
              "numAffected": 9,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Chest pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 9,
              "numAffected": 7,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 16,
              "numAffected": 13,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 7,
              "numAffected": 7,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Malaise",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Non-cardiac chest pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Oedema peripheral",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 10,
              "numAffected": 8,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "COVID-19",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Influenza",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 7,
              "numAffected": 6,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 6,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Upper respiratory tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Radiation oesophagitis",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 17,
              "numAffected": 17,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 17,
              "numAffected": 16,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 14,
              "numAffected": 14,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Radiation pneumonitis",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Radiation skin injury",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Tracheal radiation injury",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Alanine aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 10,
              "numAffected": 8,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 8,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 8,
              "numAffected": 8,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Aspartate aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 12,
              "numAffected": 9,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 12,
              "numAffected": 12,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Blood bilirubin increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 7,
              "numAffected": 6,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Blood creatine phosphokinase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Blood creatinine increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 6,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 6,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Blood fibrinogen increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Blood thyroid stimulating hormone decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Blood urea increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 8,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "C-reactive protein increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Fibrin D dimer increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Gamma-glutamyltransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Lymphocyte count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 28,
              "numAffected": 11,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 9,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 14,
              "numAffected": 9,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Monocyte count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Neutrophil count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 88,
              "numAffected": 28,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 67,
              "numAffected": 31,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 81,
              "numAffected": 24,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Platelet count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 59,
              "numAffected": 26,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 47,
              "numAffected": 24,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 38,
              "numAffected": 22,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Red blood cell count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "SARS-CoV-2 test positive",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Weight decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 11,
              "numAffected": 8,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 16,
              "numAffected": 15,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "White blood cell count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 116,
              "numAffected": 32,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 96,
              "numAffected": 31,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 87,
              "numAffected": 26,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Decreased appetite",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 37,
              "numAffected": 21,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 45,
              "numAffected": 25,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 22,
              "numAffected": 18,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypercholesterolaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 8,
              "numAffected": 6,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hyperglycaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 11,
              "numAffected": 6,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 19,
              "numAffected": 11,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 10,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypertriglyceridaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 13,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 22,
              "numAffected": 9,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 8,
              "numAffected": 6,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hyperuricaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 8,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 5,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypoalbuminaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 22,
              "numAffected": 12,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 17,
              "numAffected": 9,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 9,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypocalcaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypochloraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 6,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypokalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 12,
              "numAffected": 9,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 17,
              "numAffected": 10,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypomagnesaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hyponatraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 28,
              "numAffected": 16,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 37,
              "numAffected": 21,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 24,
              "numAffected": 16,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypoproteinaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Malnutrition",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Arthralgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 8,
              "numAffected": 6,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Bone pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Intervertebral disc protrusion",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pain in extremity",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 9,
              "numAffected": 7,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Insomnia",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 16,
              "numAffected": 12,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 12,
              "numAffected": 11,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 12,
              "numAffected": 12,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hiccups",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Laryngeal pain",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Oropharyngeal pain",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pneumonitis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Productive cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 10,
              "numAffected": 7,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Alopecia",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 32,
              "numAffected": 29,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 40,
              "numAffected": 33,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 35,
              "numAffected": 33,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Eczema",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Pruritus",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Rash",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 17,
              "numAffected": 16,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypertension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 5,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 8,
              "numAffected": 4,
              "numAtRisk": 43
            }
          ]
        },
        {
          "term": "Hypotension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "meddra 26.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 41
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 42
            },
            {
              "groupId": "EG002",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 43
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "OTHER",
        "restrictiveAgreement": true,
        "otherDetails": "BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \\& may request a further delay to protect its IP rights"
      },
      "pointOfContact": {
        "title": "Study Director",
        "organization": "BeiGene",
        "email": "clinicaltrials@beigene.com",
        "phone": "+1-877-828-5568"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2021-10-08",
          "uploadDate": "2024-07-16T18:44",
          "filename": "Prot_000.pdf",
          "size": 2342380
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2023-08-22",
          "uploadDate": "2024-07-16T18:44",
          "filename": "SAP_001.pdf",
          "size": 6385930
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-19",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2024-08-09",
            "type": "ACTUAL"
          }
        }
      }
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000707970",
          "term": "tislelizumab"
        },
        {
          "id": "D059248",
          "term": "Chemoradiotherapy"
        }
      ],
      "ancestors": [
        {
          "id": "D003131",
          "term": "Combined Modality Therapy"
        },
        {
          "id": "D013812",
          "term": "Therapeutics"
        },
        {
          "id": "D004358",
          "term": "Drug Therapy"
        },
        {
          "id": "D011878",
          "term": "Radiotherapy"
        }
      ]
    }
  },
  "hasResults": true
}